Quantum Genomics (Euronext Growth: ALQGC) (OTCQX: QNNTF) has completed patient recruitment more than six months ahead of schedule in its phase IIb hypertension study, the biopharmaceutical company revealed on Thursday.

The NEW-HOPE clinical trial will evaluate the efficacy and safety of Quantum Genomics' first-in-class drug firibastat in the treatment of high blood pressure in hypertensive patients with high cardiovascular risk.

A total of 256 subjects, of whom 54% are from minorities (African-Americans or Hispanics), were recruited throughout the US within 10 months.

Participants will receive firibastat for eight weeks (250 mg twice daily orally for two weeks, then 500 mg twice daily; hydrochlorothiazide 25 mg once daily could be added after one month if systolic blood pressure =160 mmHg and/or diastolic blood pressure =100 mmHg). The primary endpoint is change from baseline in clinic systolic blood pressure (as measured by the SPRINT method). Secondary endpoints include changes in diastolic blood pressure, ambulatory blood pressure measurements and lab tests.

Results from the trial will be released by mid-November 2018.